HEALTHCARE IS FACING A SUBSTANTIAL PARADIGM SHIFT

With the advent of the human genome and other -omes, a transformation process has started from an observation based knowledge medicine to an in addition molecular-evidence based knowledge medicine.
COMPLEXITY
IDENTIFYING PRECISE TREATMENT FOR A SINGLE PATIENT

2 micrograms of DNA

3,000,000,000 positions in human genome;
20,000 disease relevant genes

∞ infinite number of molecularly different cancers

> 8,000 approved medications *

> 10,000 clinical studies *

> 23,000,000 scientific publications *

* In early 2015, continuously growing

© 2015 Molecular Health GmbH. All rights reserved. Confidential.
We build technology-driven products that change the way diseases can be analyzed, understood and treated.

Ongoing clinical validation studies carried out in cooperation with cancer centers worldwide, like e.g. the M.D. Anderson Cancer Center (MDACC), Houston, the NCT, Heidelberg, and other so far undisclosed partners and centers ensure that our products undergo a process of continuous validation and improvement.
... you have the entire knowledge of human genes and proteins

... you can access the entire biomedical knowledge worldwide

... you can navigate through all indications of all diseases

... you have access to all known predictive biomarkers

... you know all drugs, their mechanisms of action and their interactions without redundancy
We offer access to the entire knowledge base of human genes and proteins.

We integrate all scientific publications in the relevant areas of biomedicine, mine the text to produce our own data, and provide the links to source evidences for all major data types.

We can navigate through all indications of all diseases currently known. We can identify all information that directly applies to patient disease and explore additional evidences for drugs and biomarkers beyond those found in the canons.

Biomarkers are essential for a precise molecular diagnosis, inherited disease risk analysis, analysis of drug toxicity risk, and treatment efficacy. We have developed the first-in-class biomarker database that holds thousands of individual evidences.

We have stored information about the molecular mechanism of action of drugs, their targets, metabolizing enzymes, drug-drug interactions and detailed drug development status.
Our Engines combine molecular and clinical patient data with the knowledge in Nucleus and distill the resulting information into user-friendly reports.
We are committed to the philosophy of privacy protection far in excess of known standards.

Molecular Health

- is using interpreted and outcomes data anonymously to train its treatment decision and patient safety support systems to improve the quality of treatment for the benefit of all patients.

- does not commercialize patients' molecular data.

- is committed to handle Patient Data anonymously.

- applies strict data protection and data privacy standards.